Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors

Prostatic Neoplasms Clinical Trial

Official title:

Development and Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05335967
• Other study ID #: 201902235B0C601
• Status: Recruiting
• Phase: N/A
• Start date: May 20, 2022
• Est. completion date: July 31, 2024

Study information

• Verified date: September 2023
• Source: National Taipei University of Nursing and Health Sciences
• Contact: Ching-Hui Chien, PhD
• Phone: +886-2-28227101
• Email: chinghui[@]ntunhs.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objectives: This project aims to develop a self-management program for survivors with prostate cancer experiencing urinary incontinence following radical prostatectomy and determine its effectiveness.

Methods: The investigators will develop a self-management program and conduct a pilot study on survivors with prostate cancer experiencing urinary incontinence following radical prostatectomy. And the investigators will test the effectiveness of the self-management program. After completing a pretest, participants will be randomly assigned to the experimental or control group. The self-management group will receive the self-management program for 12 weeks, whereas the information group will receive an information package on a healthy diet. Posttests will be administered 12 and 16 weeks after the pretest. The study variables will include physical symptoms and bothers, cancer-related self-efficacy, social participation, demoralization, and resilience.

Description:

Objectives: This project aims to develop a self-management program for survivors with prostate cancer experiencing urinary incontinence following radical prostatectomy and determine its effectiveness.

Methods: The investigators will develop a self-management program and conduct a pilot study on survivors with prostate cancer experiencing urinary incontinence following radical prostatectomy. And the investigators will test the effectiveness of the self-management program. After completing a pretest, participants will be randomly assigned to the experimental or control group. The self-management group will receive the self-management program for 12 weeks, whereas the information group will receive an information package on a healthy diet. The self-management program is included a self-management application, a self-management manual, and professional support. The information package consists of a manual on a healthy diet and a multimedia film on a healthy diet. Posttests will be administered 12 and 16 weeks after the pretest. The study variables will include physical symptoms and bothers, cancer-related self-efficacy, social participation, demoralization, and resilience. The statistical analyses will consist of independent sample t-tests, Chi-squire, and generalized estimating equation analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

Prostate cancer survivors will include if they fit the following:

• Received radical prostatectomy and suffering from urinary incontinence for at least one week

• Eastern Cooperative Oncology Group 0-1 point, able to walk entirely independently

• Have a smartphone or a tablet with a wireless network

• Their intimate partner or one of the family members willing to learn together

• Agreed to participate in the study and completed the informed consent form

Exclusion Criteria:

Prostate cancer survivors will be excluded if they had one or more of the following:

• A request, with the consideration of family members, that the medical team not tell the patient about the diagnosis or condition of the disease

• A history of psychiatric illness, such as dementia, depression; schizophrenia, or bipolar disorder

• Suffer from other types of cancer and actively undergoing treatment

Related Conditions & MeSH terms

• Prostatic Neoplasms
• Self-Management

Intervention

Behavioral:
• Self-management program
The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.

Other:
• Information package
The patients in this group will receive an information package on a healthy diet.

Locations

Country	Name	City	State
Taiwan	Chang Gung Memorial Hospital at Keelung	Keelung
Taiwan	Chang Gung Memorial Hospital at Linkou	Taoyuan

Sponsors (3)

Lead Sponsor	Collaborator
National Taipei University of Nursing and Health Sciences	Chang Gung Memorial Hospital, National Science and Technology Council

Country where clinical trial is conducted

Taiwan, 

References & Publications (26)

Agochukwu NQ, Skolarus TA, Wittmann D. Telemedicine and prostate cancer survivorship: a narrative review. Mhealth. 2018 Oct 8;4:45. doi: 10.21037/mhealth.2018.09.08. eCollection 2018. — View Citation

An E, Lo C, Hales S, Zimmermann C, Rodin G. Demoralization and death anxiety in advanced cancer. Psychooncology. 2018 Nov;27(11):2566-2572. doi: 10.1002/pon.4843. Epub 2018 Aug 20. — View Citation

Baker H, Wellman S, Lavender V. Functional Quality-of-Life Outcomes Reported by Men Treated for Localized Prostate Cancer: A Systematic Literature Review. Oncol Nurs Forum. 2016 Mar;43(2):199-218. doi: 10.1188/16.ONF.199-218. — View Citation

Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977 Mar;84(2):191-215. doi: 10.1037//0033-295x.84.2.191. No abstract available. — View Citation

Campbell-Sills L, Stein MB. Psychometric analysis and refinement of the Connor-davidson Resilience Scale (CD-RISC): Validation of a 10-item measure of resilience. J Trauma Stress. 2007 Dec;20(6):1019-28. doi: 10.1002/jts.20271. — View Citation

Chien CH, Chuang CK, Liu KL, Huang XY, Liu HE. Psychosocial adjustments in patients with prostate cancer from pre-diagnosis to 6 months post-treatment. Int J Nurs Pract. 2016 Feb;22(1):70-8. doi: 10.1111/ijn.12360. Epub 2014 Oct 13. — View Citation

Chien CH, Chung HJ, Liu KL, Pang ST, Wu CT, Chang YH, Huang XY, Chang YH, Lin TP, Lin WY, Chuang CK. Effectiveness of a couple-based psychosocial intervention on patients with prostate cancer and their partners: A quasi-experimental study. J Adv Nurs. 2020 Oct;76(10):2572-2585. doi: 10.1111/jan.14471. Epub 2020 Aug 3. — View Citation

Chou MC, Chien CH, Chung HJ, Chuang CK, Wu CT, Pang ST, Liu KL, Chang YH. The Psychometric Properties of Taiwanese Version of the Memorial Anxiety Scale for Prostate Cancer. J Pain Symptom Manage. 2021 Apr;61(4):824-830. doi: 10.1016/j.jpainsymman.2020.10.013. Epub 2020 Oct 24. — View Citation

Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. Psychooncology. 2010 Sep;19(9):909-22. doi: 10.1002/pon.1657. — View Citation

Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82. doi: 10.1002/da.10113. — View Citation

Crafoord MT, Fjell M, Sundberg K, Nilsson M, Langius-Eklof A. Engagement in an Interactive App for Symptom Self-Management during Treatment in Patients With Breast or Prostate Cancer: Mixed Methods Study. J Med Internet Res. 2020 Aug 10;22(8):e17058. doi: 10.2196/17058. Erratum In: J Med Internet Res. 2021 Oct 12;23(10):e33140. — View Citation

Faithfull S, Cockle-Hearne J, Khoo V. Self-management after prostate cancer treatment: evaluating the feasibility of providing a cognitive and behavioural programme for lower urinary tract symptoms. BJU Int. 2011 Mar;107(5):783-790. doi: 10.1111/j.1464-410X.2010.09588.x. Epub 2010 Oct 13. — View Citation

Foster C, Breckons M, Cotterell P, Barbosa D, Calman L, Corner J, Fenlon D, Foster R, Grimmett C, Richardson A, Smith PW. Cancer survivors' self-efficacy to self-manage in the year following primary treatment. J Cancer Surviv. 2015 Mar;9(1):11-9. doi: 10.1007/s11764-014-0384-0. Epub 2014 Jul 16. — View Citation

Foster C, Fenlon D. Recovery and self-management support following primary cancer treatment. Br J Cancer. 2011 Nov 8;105 Suppl 1(Suppl 1):S21-8. doi: 10.1038/bjc.2011.419. — View Citation

Frankland J, Brodie H, Cooke D, Foster C, Foster R, Gage H, Jordan J, Mesa-Eguiagaray I, Pickering R, Richardson A. Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. BMC Cancer. 2019 Apr 23;19(1):368. doi: 10.1186/s12885-019-5561-0. — View Citation

Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castaneda-Orjuela CA, Catala-Lopez F, Choi JJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, das Neves J, Dey S, Dharmaratne SD, Doku DT, Driscoll TR, Dubey M, Ebrahimi H, Edessa D, El-Khatib Z, Endries AY, Fischer F, Force LM, Foreman KJ, Gebrehiwot SW, Gopalani SV, Grosso G, Gupta R, Gyawali B, Hamadeh RR, Hamidi S, Harvey J, Hassen HY, Hay RJ, Hay SI, Heibati B, Hiluf MK, Horita N, Hosgood HD, Ilesanmi OS, Innos K, Islami F, Jakovljevic MB, Johnson SC, Jonas JB, Kasaeian A, Kassa TD, Khader YS, Khan EA, Khan G, Khang YH, Khosravi MH, Khubchandani J, Kopec JA, Kumar GA, Kutz M, Lad DP, Lafranconi A, Lan Q, Legesse Y, Leigh J, Linn S, Lunevicius R, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, McMahon BJ, Meier T, Melaku YA, Melku M, Memiah P, Mendoza W, Meretoja TJ, Mezgebe HB, Miller TR, Mohammed S, Mokdad AH, Moosazadeh M, Moraga P, Mousavi SM, Nangia V, Nguyen CT, Nong VM, Ogbo FA, Olagunju AT, Pa M, Park EK, Patel T, Pereira DM, Pishgar F, Postma MJ, Pourmalek F, Qorbani M, Rafay A, Rawaf S, Rawaf DL, Roshandel G, Safiri S, Salimzadeh H, Sanabria JR, Santric Milicevic MM, Sartorius B, Satpathy M, Sepanlou SG, Shackelford KA, Shaikh MA, Sharif-Alhoseini M, She J, Shin MJ, Shiue I, Shrime MG, Sinke AH, Sisay M, Sligar A, Sufiyan MB, Sykes BL, Tabares-Seisdedos R, Tessema GA, Topor-Madry R, Tran TT, Tran BX, Ukwaja KN, Vlassov VV, Vollset SE, Weiderpass E, Williams HC, Yimer NB, Yonemoto N, Younis MZ, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706. — View Citation

Jonkman NH, Schuurmans MJ, Groenwold RHH, Hoes AW, Trappenburg JCA. Identifying components of self-management interventions that improve health-related quality of life in chronically ill patients: Systematic review and meta-regression analysis. Patient Educ Couns. 2016 Jul;99(7):1087-1098. doi: 10.1016/j.pec.2016.01.022. Epub 2016 Feb 1. — View Citation

Kissane DW, Wein S, Love A, Lee XQ, Kee PL, Clarke DM. The Demoralization Scale: a report of its development and preliminary validation. J Palliat Care. 2004 Winter;20(4):269-76. — View Citation

Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003 Aug;26(1):1-7. doi: 10.1207/S15324796ABM2601_01. — View Citation

Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, Holland JC, Breitbart W. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer. 2003 Jun 1;97(11):2910-8. doi: 10.1002/cncr.11386. — View Citation

Sharpley CF, Bitsika V, Christie DRH, Bradford R, Steigler A, Denham JW. Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation. J Psychosoc Oncol. 2017 Jul-Aug;35(4):438-450. doi: 10.1080/07347332.2017.1306733. Epub 2017 Mar 20. — View Citation

Skolarus TA, Metreger T, Wittmann D, Hwang S, Kim HM, Grubb RL 3rd, Gingrich JR, Zhu H, Piette JD, Hawley ST. Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. J Clin Oncol. 2019 May 20;37(15):1326-1335. doi: 10.1200/JCO.18.01770. Epub 2019 Mar 29. — View Citation

Song L, Guo P, Tan X, Chen RC, Nielsen ME, Birken SA, Koontz BF, Northouse LL, Mayer DK. Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused web-based, mHealth program: the results of a pilot feasibility study. J Cancer Surviv. 2021 Feb;15(1):99-108. doi: 10.1007/s11764-020-00914-7. Epub 2020 Jul 17. — View Citation

Straczynska A, Weber-Rajek M, Strojek K, Piekorz Z, Styczynska H, Goch A, Radziminska A. The Impact Of Pelvic Floor Muscle Training On Urinary Incontinence In Men After Radical Prostatectomy (RP) - A Systematic Review. Clin Interv Aging. 2019 Nov 12;14:1997-2005. doi: 10.2147/CIA.S228222. eCollection 2019. — View Citation

Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905. doi: 10.1016/s0090-4295(00)00858-x. — View Citation

Xu A, Wang Y, Wu X. Effectiveness of e-health based self-management to improve cancer-related fatigue, self-efficacy and quality of life in cancer patients: Systematic review and meta-analysis. J Adv Nurs. 2019 Dec;75(12):3434-3447. doi: 10.1111/jan.14197. Epub 2019 Oct 20. — View Citation

* Note: There are 26 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Demographic characteristic and disease information list 1	Age	Pre-test
Other	Demographic characteristic and disease information list 2	Marital status	Pre-test
Other	Demographic characteristic and disease information list 3	Education level	Pre-test
Other	Demographic characteristic and disease information list 4	Religious beliefs	Pre-test
Other	Demographic characteristic and disease information list 5	Employment status	Pre-test
Other	Demographic characteristic and disease information list 6	Cancer stage	Pre-test
Other	Demographic characteristic and disease information list 7	Chronic disease history	Pre-test
Other	Demographic characteristic and disease information list 8	Time of diagnosis (months)	Pre-test
Other	Demographic characteristic and disease information list 9	Treatment methods	Pre-test
Other	Demographic characteristic and disease information list 10	Latest serum level of prostate-specific antigen (ng/mL)	Pre-test
Other	Demographic characteristic and disease information list 11	Latest serum level of prostate-specific antigen (ng/mL)	12 weeks after the pretest
Other	Demographic characteristic and disease information list 12	Latest serum level of prostate-specific antigen (ng/mL)	16 weeks after the pretest
Other	Satisfaction and evaluation of self-management intervention	Self-designed five items will be used to assess these outcomes.Each item is scaled from 0 (worst) to 100 (best).	12 weeks after the pretest
Primary	Urinary symptoms and bothers	The Mandarin version of the Expanded Prostate Cancer Index Composite (EPIC) will be used to measure the urinary symptoms and bother of the participants. Total 7 items and each question is linearly scaled from 0 (worst) to 100 (best).	Pre-test
Primary	Urinary symptoms and bothers	The Mandarin version of the Expanded Prostate Cancer Index Composite (EPIC) will be used to measure the urinary symptoms and bother of the participants. Total 7 items and each question is linearly scaled from 0 (worst) to 100 (best).	12 weeks after the pretest
Primary	Urinary symptoms and bothers	The Mandarin version of the Expanded Prostate Cancer Index Composite (EPIC) will be used to measure the urinary symptoms and bother of the participants. Total 7 items and each question is linearly scaled from 0 (worst) to 100 (best).	16 weeks after the pretest
Primary	Cancer related self-efficacy	The Mandarin version of the Cancer Survivors' Self-Efficacy Scale (CSSES) will be used to evaluate the cancer-specific self-efficacy of participants.The total score ranges from 11 to 110; the lower the score, the worse the self-efficacy.	Pre-test
Primary	Cancer related self-efficacy	The Mandarin version of the Cancer Survivors' Self-Efficacy Scale (CSSES) will be used to evaluate the cancer-specific self-efficacy of participants.The total score ranges from 11 to 110; the lower the score, the worse the self-efficacy.	12 weeks after the pretest
Primary	Cancer related self-efficacy	The Mandarin version of the Cancer Survivors' Self-Efficacy Scale (CSSES) will be used to evaluate the cancer-specific self-efficacy of participants.The total score ranges from 11 to 110; the lower the score, the worse the self-efficacy.	16 weeks after the pretest
Secondary	Social participation	The Mandarin version of the Older Adults Social Participation Scale will be used to assess participants' social participation. The scale includes 12 items with a score range of 12 to 60. A higher score shows a higher degree of social participation.	Pre-test
Secondary	Social participation	The Mandarin version of the Older Adults Social Participation Scale will be used to assess participants' social participation. The scale includes 12 items with a score range of 12 to 60. A higher score shows a higher degree of social participation.	12 weeks after the pretest
Secondary	Social participation	The Mandarin version of the Older Adults Social Participation Scale will be used to assess participants' social participation. The scale includes 12 items with a score range of 12 to 60. A higher score shows a higher degree of social participation.	16 weeks after the pretest
Secondary	Demoralization	The Mandarin version of the Demoralization Scale will be used to assess participants' demoralization. The scale includes 24 items, and the score range is 0-96. A higher score means higher demoralization.	Pre-test
Secondary	Demoralization	The Mandarin version of the Demoralization Scale will be used to assess participants' demoralization. The scale includes 24 items, and the score range is 0-96. A higher score means higher demoralization.	12 weeks after the pretest
Secondary	Demoralization	The Mandarin version of the Demoralization Scale will be used to assess participants' demoralization. The scale includes 24 items, and the score range is 0-96. A higher score means higher demoralization.	16 weeks after the pretest
Secondary	Resilience	The Mandarin version of the Connor-Davidson Resilience Scale will be used to measure the psychological resilience of participants. The scale has 10 items, and the score range is 0-100. A higher score reflects better resilience.	Pre-test
Secondary	Resilience	The Mandarin version of the Connor-Davidson Resilience Scale will be used to measure the psychological resilience of participants. The scale has 10 items, and the score range is 0-100. A higher score reflects better resilience.	12 weeks after the pretest
Secondary	Resilience	The Mandarin version of the Connor-Davidson Resilience Scale will be used to measure the psychological resilience of participants. The scale has 10 items, and the score range is 0-100. A higher score reflects better resilience.	16 weeks after the pretest